Binary Drug Reinforced First Small-Molecule-Based Prodrug for Synergistic Anticancer Effects

Area of Science:

• Biomedical Engineering
• Drug Delivery Systems
• Oncology

Background:

• Cancer cells overexpress hydrogen peroxide (H2O2), a key target for drug delivery.
• Developing effective drug delivery systems is crucial for improving cancer therapy outcomes.
• Prodrug strategies offer targeted drug release mechanisms.

Purpose of the Study:

• To develop and evaluate a small-molecule-based binary drug delivery system (BDDS).
• To utilize intracellular H2O2 for triggered release of two anticancer drugs: SN-38 and 5'-DFUR.
• To compare the efficacy of the BDDS with a single drug delivery system (SDDS).

Main Methods:

• Synthesis of a novel small-molecule-based binary drug delivery system (BDDS).
• Incorporation of two anticancer drugs, SN-38 and 5'-DFUR, into the BDDS.
• In vitro/in vivo studies to assess drug release triggered by H2O2.
• Comparative efficacy studies against a single drug conjugate (SDDS) and control groups.

Main Results:

• Successful development of a prodrug BDDS capable of releasing SN-38 and 5'-DFUR.
• Drug release was effectively triggered by intracellular H2O2, a marker overexpressed in cancer cells.
• The BDDS demonstrated superior anticancer efficacy compared to the SDDS in preliminary studies.

Conclusions:

• The developed BDDS represents a promising strategy for targeted cancer therapy.
• H2O2-triggered drug release offers a selective mechanism for activating anticancer agents within tumor cells.
• Further investigation into the BDDS is warranted to explore its full therapeutic potential in oncology.